Infection by CXCR4-tropic human immunodeficiency virus type 1 is inhibited by the cationic cell-penetrating peptide derived from HIV-1 tat

International Journal of Peptides

Volumn 2012, Issue , 2012, Pages

  Keogan, Shawn ^a   Passic, Shendra ^a   Krebs, Fred C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CATION; CELL PENETRATING PEPTIDE; CHEMOKINE RECEPTOR CXCR4; LYSINE; PROTEIN VARIANT; TRANSACTIVATOR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 84874740845     PISSN: 16879767     EISSN: 16879775     Source Type: Journal    
DOI: 10.1155/2012/349427     Document Type: Article

References (28)

1. Foerg C., Weller K. M., Rechsteiner H., Nielsen H. M., Fernndez-Carneado J., Brunisholz R., Giralt E., Merkle H. P., Metabolic cleavage and translocation efficiency of selected cell penetrating peptides: a comparative study with epithelial cell cultures American Association of Pharmaceutical Scientists Journal 2008 10 2 349 359
2. Nakase I., Takeuchi T., Tanaka G., Futaki S., Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides Advanced Drug Delivery Reviews 2008 60 4-5 598 607 (Pubitemid 351215576)
3. Torchilin V. P., Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers Advanced Drug Delivery Reviews 2008 60 4-5 548 558 (Pubitemid 351215572)
4. Jones A. T., Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides International Journal of Pharmaceutics 2008 354 1-2 34 38
5. Gump J. M., Dowdy S. F., TAT transduction: the molecular mechanism and therapeutic prospects Trends in Molecular Medicine 2007 13 10 443 448 (Pubitemid 47562310)
6. Brooks H., Lebleu B., Vivs E., Tat peptide-mediated cellular delivery: back to basics Advanced Drug Delivery Reviews 2005 57 4 559 577 (Pubitemid 40255561)
7. Mishra A., Lai G. H., Schmidt N. W., Sun V. Z., Rodriguez A. R., Tong R., Tang L., Cheng J., Deming T. J., Kamei D. T., Wong G. C. L., Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions Proceedings of the National Academy of Sciences of the United States of America 2011 108 41 16883 16888
8. Doranz B. J., Grovit-Ferbas K., Sharron M. P., Mao S. H., Goetz M. B., Daar E. S., Doms R. W., O'Brien W. A., A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor Journal of Experimental Medicine 1997 186 8 1395 1400 (Pubitemid 27469036)
9. Lapidot A., Peled A., Berchanski A., Pal B., Kollet O., Lapidot T., Borkow G., NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity Biochimica et Biophysica Acta 2008 1780 6 914 920
10. Lee-Huang S., Maiorov V., Huang P. L., Ng A., Hee C. L., Chang Y. T., Kallenbach N., Huang P. L., Chen H. C., Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity Biochemistry 2005 44 12 4648 4655 (Pubitemid 40396743)
11. Bergman P., Walter-Jallow L., Broliden K., Agerberth B., Sderlund J., The antimicrobial peptide LL-37 inhibits HIV-1 replication Current HIV Research 2007 5 4 410 415 (Pubitemid 47040482)
12. Krebs F. C., Miller S. R., Ferguson M. L., Labib M., Rando R. F., Wigdahl B., Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1 Biomedicine and Pharmacotherapy 2005 59 8 438 445 (Pubitemid 41383837)
13. Passic S. R., Ferguson M. L., Catalone B. J., Kish-Catalone T., Kholodovych V., Zhu W., Welsh W., Rando R., Howett M. K., Wigdahl B., Labib M., Krebs F. C., Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1 Biomedicine and Pharmacotherapy 2010 64 10 723 732
14. Thakkar N., Pirrone V., Passic S., Keogan S., Zhu W., Kholodovych V., Welsh W., Rando R., Labib M., Wigdahl B., Krebs F. C., Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection Antimicrobial Agents and Chemotherapy 2010 54 5 1965 1972
15. Thakkar N., Pirrone V., Passic S., Zhu W., Kholodovych V., Welsh W., Rando R. F., Labib M. E., Wigdahl B., Krebs F. C., Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection Antimicrobial Agents and Chemotherapy 2009 53 2 631 638
16. Lozenski K., Kish-Catalone T., Pirrone V., Cervicovaginal safety of the formulated biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model of microbicide application Journal of Biomedicine and Biotechnology 2011 2011 10
17. Wilkinson R. A., Pincus S. H., Shepard J. B., Walton S. K., Bergin E. P., Labib M., Teintze M., Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4 Antimicrobial Agents and Chemotherapy 2011 55 1 255 263
18. Martellini J. A., Cole A. L., Venkataraman N., Quinn G. A., Svoboda P., Gangrade B. K., Pohl J., Srensen O. E., Cole A. M., Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma FASEB Journal 2009 23 10 3609 3618
19. Venkataraman N., Cole A. L., Svoboda P., Pohl J., Cole A. M., Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid Journal of Immunology 2005 175 11 7560 7567 (Pubitemid 41713455)
20. Xiao H., Neuveut C., Tiffany H. L., Benkirane M., Rich E. A., Murphy P. M., Jeang K. T., Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1 Proceedings of the National Academy of Sciences of the United States of America 2000 97 21 11466 11471
21. Kuppuswamy M., Subramanian T., Srinivasan A., Chinnadurai G., Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis Nucleic Acids Research 1989 17 9 3551 3561 (Pubitemid 19120452)
22. Cardozo A. K., Buchillier V., Mathieu M., Chen J., Ortis F., Ladrire L., Allaman-Pillet N., Poirot O., Kellenberger S., Beckmann J. S., Eizirik D. L., Bonny C., Maurer F., Cell-permeable peptides induce dose- and length-dependent cytotoxic effects Biochimica et Biophysica Acta 2007 1768 9 2222 2234 (Pubitemid 47379621)
23. Ensoli B., Barillari G., Salahuddin S. Z., Gallo R. C., Wong-Staal F., Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients Nature 1990 345 6270 84 86
24. Nath A., Psooy K., Martin C., Knudsen B., Magnuson D. S. K., Haughey N., Geiger J. D., Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic Journal of Virology 1996 70 3 1475 1480 (Pubitemid 26062905)
25. Campbell G. R., Pasquier E., Watkins J., Bourgarel-Rey V., Peyrot V., Esquieu D., Barbier P., de Mareuil J., Braguer D., Kaleebu P., Yirrell D. L., Loret E. P., The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis Journal of Biological Chemistry 2004 279 46 48197 48204 (Pubitemid 39540975)
26. Chauhan A., Tikoo A., Kapur A. K., Singh M., The taming of the cell penetrating domain of the HIV Tat: myths and realities Journal of Controlled Release 2007 117 2 148 162 (Pubitemid 46172502)
27. Romani B., Engelbrecht S., Glashoff R. H., Functions of Tat: the versatile protein of human immunodeficiency virus type 1 Journal of General Virology 2010 91, part 1 1 12
28. Rothbard J. B., Jessop T. C., Lewis R. S., Murray B. A., Wender P. A., Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells Journal of the American Chemical Society 2004 126 31 9506 9507 (Pubitemid 39031015)